We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Invitrogen Reaches Key Milestone in its Agreement with Blue Heron Biotechnology
News

Invitrogen Reaches Key Milestone in its Agreement with Blue Heron Biotechnology

Invitrogen Reaches Key Milestone in its Agreement with Blue Heron Biotechnology
News

Invitrogen Reaches Key Milestone in its Agreement with Blue Heron Biotechnology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Invitrogen Reaches Key Milestone in its Agreement with Blue Heron Biotechnology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Invitrogen Corporation has reached a key milestone in its agreement with Blue Heron Biotechnology and is now the co-exclusive worldwide distributor with Blue Heron for its custom gene synthesis services.

Blue Heron Biotechnology says that its proprietary GeneMaker® platform can synthesize gene sequences with perfect accuracy which makes it ideal for researchers studying anything from single genes up to entire genomes as in the biofuels and synthetic biology markets.

Researchers worldwide are increasingly turning to synthetic genes as a convenient, cost-effective alternative for traditional cloning. Synthetic genes have allowed pharmaceutical and biotechnology companies to speed the drug discovery process by rapidly and accurately synthesizing genes of interest that are in turn used to produce novel proteins, new vaccines and diagnostics.

"For decades, researchers have depended on Invitrogen's cloning platforms and gene collections to advance their gene discovery and functional genomics experiments. With new technologies that allow the economical production of synthetic genes, researchers can expand the possibilities of science," said Dr. Balwant Patel, general manager for Cloning and Protein Expression at Invitrogen.

"Our relationship with Blue Heron means that our customers will explore those possibilities with the best synthetic genetics technologies and the most highly regarded cloning and expression platforms available commercially," Dr. Patel added.

"This relationship creates unique opportunities to serve the needs of the research community. We are very enthusiastic about bringing Blue Heron's technological leadership in gene synthesis to Invitrogen's unmatched worldwide customer base," said John Fess, CEO of Blue Heron.

Advertisement